Transposon mutagenesis identifies genetic drivers of BrafV600E melanoma

被引:52
|
作者
Mann, Michael B. [1 ,2 ]
Black, Michael A. [3 ]
Jones, Devin J. [1 ]
Ward, Jerrold M. [2 ]
Yew, Christopher Chin Kuan [2 ]
Newberg, Justin Y. [1 ]
Dupuy, Adam J. [4 ]
Rust, Alistair G. [5 ]
Bosenberg, Marcus W. [6 ,7 ]
McMahon, Martin [8 ,9 ]
Print, Cristin G. [10 ,11 ]
Copeland, Neal G. [1 ,2 ]
Jenkins, Nancy A. [1 ,2 ]
机构
[1] Houston Methodist Res Inst, Canc Res Program, Houston, TX 77030 USA
[2] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore
[3] Univ Otago, Dept Biochem, Dunedin, New Zealand
[4] Univ Iowa, Carver Coll Med, Dept Anat & Cell Biol, Iowa City, IA USA
[5] Wellcome Trust Sanger Inst, Expt Canc Genet, Hinxton, Cambs, England
[6] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA
[7] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[8] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[9] Univ Calif San Francisco, Dept Cell & Mol Pharmacol, San Francisco, CA 94143 USA
[10] Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand
[11] Univ Auckland, New Zealand Bioinformat Inst, Auckland 1, New Zealand
关键词
GENOME-WIDE ASSOCIATION; LONG NONCODING RNAS; SUSCEPTIBILITY LOCUS; MOUSE MODEL; CANCER; MUTATIONS; KINASE; PTEN; LANDSCAPE; DISCOVERY;
D O I
10.1038/ng.3275
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Although nearly half of human melanomas harbor oncogenic BRAF(V600E) mutations, the genetic events that cooperate with these mutations to drive melanogenesis are still largely unknown. Here we show that Sleeping Beauty (SB) transposon-mediated mutagenesis drives melanoma progression in Braf(V600E) mutant mice and identify 1,232 recurrently mutated candidate cancer genes (CCGs) from 70 SB-driven melanomas. CCGs are enriched in Wnt, PI3K, MAPK and netrin signaling pathway components and are more highly connected to one another than predicted by chance, indicating that SB targets cooperative genetic networks in melanoma. Human orthologs of >500 CCGs are enriched for mutations in human melanoma or showed statistically significant clinical associations between RNA abundance and survival of patients with metastatic melanoma. We also functionally validate CEP350 as a new tumor-suppressor gene in human melanoma. SB mutagenesis has thus helped to catalog the cooperative molecular mechanisms driving BRAF(V600E) melanoma and discover new genes with potential clinical importance in human melanoma.
引用
收藏
页码:486 / U86
页数:13
相关论文
共 50 条
  • [1] Transposon mutagenesis identifies genetic drivers of BrafV600E melanoma
    Michael B Mann
    Michael A Black
    Devin J Jones
    Jerrold M Ward
    Christopher Chin Kuan Yew
    Justin Y Newberg
    Adam J Dupuy
    Alistair G Rust
    Marcus W Bosenberg
    Martin McMahon
    Cristin G Print
    Neal G Copeland
    Nancy A Jenkins
    Nature Genetics, 2015, 47 : 486 - 495
  • [2] A gain-of-function screen identifies drivers of drug resistance in BRAFV600E melanoma cell lines
    Feddersen, Charlotte R.
    Schillo, Jacob L.
    Vaughn, Hayley R.
    Voigt, Andrew P.
    Zhu, Eliot Y.
    Wadsworth, Lexy S.
    Stipp, Christopher S.
    Dupuy, Adam J.
    CANCER RESEARCH, 2018, 78 (13)
  • [3] cAMP signaling in BRAFV600E melanoma
    Rodriguez, Carlos I.
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Modulation of MHC expression by BRAFV600E in melanoma
    Pollack, B. P.
    Sapkota, B.
    Hill, C. E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S224 - S224
  • [5] BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
    J S Wilmott
    A M Menzies
    L E Haydu
    D Capper
    M Preusser
    Y E Zhang
    J F Thompson
    R F Kefford
    A von Deimling
    R A Scolyer
    G V Long
    British Journal of Cancer, 2013, 108 : 924 - 931
  • [6] Intrapatient Homogeneity of BRAFV600E Expression in Melanoma
    Menzies, Alexander M.
    Lum, Trina
    Wilmott, James S.
    Hyman, Jessica
    Kefford, Richard F.
    Thompson, John F.
    O'Toole, Sandra
    Long, Georgina V.
    Scolyer, Richard A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (03) : 377 - 382
  • [7] BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
    Wilmott, J. S.
    Menzies, A. M.
    Haydu, L. E.
    Capper, D.
    Preusser, M.
    Zhang, Y. E.
    Thompson, J. F.
    Kefford, R. F.
    von Deimling, A.
    Scolyer, R. A.
    Long, G. V.
    BRITISH JOURNAL OF CANCER, 2013, 108 (04) : 924 - 931
  • [8] Melanoma Drug Approved for Patients With BRAFV600E
    Smart, Michael
    ONCOLOGY NURSING FORUM, 2011, 38 (06) : 739 - 740
  • [9] Expression of AID in malignant melanoma with BRAFV600E mutation
    Nakamura, M.
    Okura, R.
    Yoshioka, H.
    Yoshioka, M.
    Hiromasa, K.
    Nishio, D.
    FEBS JOURNAL, 2014, 281 : 465 - 465
  • [10] Controversies in Intrapatient Melanoma BRAFV600E Mutation Status
    Riveiro-Falkenbach, Erica
    Santos-Briz, Angel
    Rios-Martin, Juan J.
    Rodriguez-Peralto, Jose L.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2017, 39 (04) : 291 - 295